ClinicalTrials.gg
RecruitingNCT06595459Updated Jun 22, 2026

The Options 2 Study

A Phase 4 interventional study of Nicotine Pouches and Mini Nicotine lozenges in Smoker and Smoking Cessation, sponsored by University of Wisconsin, Madison. Recruiting at 1 site in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-06-22.

Sponsored by University of Wisconsin, Madison · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Smoking Cessation by University of Wisconsin, Madison — 3 open to participants now, 3 under way, none of them phase 3. Smoking Cessation · University of Wisconsin, Madison.

Planned enrollment
20th of 32
300 · median 561
Started
2025
the only one that year
Phase 4
18 of 33
3 open now
Registered
31st of 33
by date

Among the 33 studies in Smoking Cessation by University of Wisconsin, Madison, this one is the 20th largest by planned enrollment of the 32 interventional ones that give a count, is the only one that started in 2025, is one of 18 in phase 4, and was the 31st registered.

Smoking Cessation

1,583 studies on the registry are indexed under Smoking Cessation; 196 are open to participants now.

Browse Smoking Cessation studies →

Open to participants now

3 of the 33 studies in Smoking Cessation by University of Wisconsin, Madison are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 134 Smoking Cessation studies recruiting now, 92 (69%) set no upper age limit and 35 (26%) stop at 75 or younger; 6 take children under 18; 40 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Smoking Cessation by University of Wisconsin, Madison, or all of them as a file.
02

Study summary

The goal of this clinical trial is to investigate how well nicotine pouches and nicotine mini lozenges serve as substitutes for cigarettes when people try to switch from smoking to using these alternate nicotine products.

Participants will:

  • Use nicotine pouches, nicotine mini lozenges, or no study product for a week and then try not to smoke for 3 weeks.
  • Have 6 in-person research visits and 1 follow-up call
  • Complete questionnaires at each study contact and use a smartphone app to record smoking and study product use
Read the detailed description

Researchers currently lack critical data needed to appraise the potential for nicotine pouches to benefit public health. Specifically, they do not know how readily smokers will adopt pouches, how effectively they can substitute for cigarettes when smokers are trying to avoid smoking, the role of nicotine dose in the ability of pouches to serve as a substitute, or the mechanisms that facilitate or hinder successful product transition. This study will address these questions using a 4-arm randomized controlled trial of adults who smoke ≥5 cigarettes daily and are not planning to quit smoking in the next 30 days. This study will provide a rigorous evaluation of the potential efficacy of a relatively modified risk new nicotine product as a substitute for combusted cigarettes. The head-to-head comparison with FDA-approved mini lozenges can inform tobacco regulatory policy decisions.

03

Conditions studied

  • Smoker
  • Smoking Cessation

Browse trials for

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥ 21 years old (i.e., able to legally purchase tobacco products)
  • able to read and communicate in English
  • no plans to quit smoking in the next 30 days
  • willing to stop using nicotine replacement or varenicline
  • willing to stop using bupropion (i.e., Wellbutrin, Zyban) if they are currently using it only for smoking cessation
  • smoking ≥ 5 cigarettes per day for the past 6 months
  • exhaled carbon monoxide ≥ 6 ppm
  • no nicotine pouch or smokeless tobacco (including snus) use within the last 6 months

Exclusion criteria

Exclusion Criteria:

  • currently in treatment for psychosis or bipolar disorder
  • currently taking bupropion for non-smoking cessation reasons (e.g., Wellbutrin for depression)
  • currently pregnant or breastfeeding
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    3mg Nicotine Pouches

    Participants will use 3mg nicotine pouches

    Drug: Nicotine Pouches

  • Experimental
    6mg Nicotine Pouches

    Participants will use 6mg nicotine pouches

    Drug: Nicotine Pouches

  • Experimental
    Nicotine Mini Lozenges

    Participants will use mini lozenges with dosing based on time to first cigarette (2mg or 4mg)

    Drug: Mini Nicotine lozenges

  • No intervention
    No Study Product

    Participants randomized to this arm will use a mint candy during two different 30-minute laboratory sessions only.

Interventions

06

What researchers measure

Primary outcomes

  1. Mean number of cigarettes smoked per day during the 21-day switching period.

    Participants will self-report on their cigarette use

    Time frame: Baseline to 3 weeks

Secondary outcomes

  1. Change in cigarette craving

    Participants will rate their craving for a cigarette using a 0-100 visual analog scale, where 0 = no craving and 100 = extreme craving after sampling their assigned study product after overnight abstinence from smoking

    Time frame: Baseline to 3 weeks

  2. Mean units of study product used per day during the 7-days prior to the switching period

    Participants will report their study product use via EMA

    Time frame: For 7-days leading up to the switching period

  3. Mean units of study product used per day during the 21-day of the switching period

    Participants will report their study product use via EMA

    Time frame: 21-days of the switching period

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Jan 2029, 43 months after the start.

Of 53 non-industry phase 4 interventional studies under Smoking Cessation, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 55. This study's planned 43 months is above that.

Counting every sponsor, half of 56 studies reached it within 35 months; a quarter within 21 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2024
First posted
Sep 19, 2024
StartActual
May 21, 2025
Primary completionEst.
Jan 1, 2029
CompletionEst.
Jul 30, 2029
Last update
Jun 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06595459
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
May 21, 2025
Primary completion
Jan 1, 2029 (estimated)
Completion
Jul 30, 2029 (estimated)
Last update
Jun 22, 2026

Study contacts

Megan Piper, PhD
Contact
mep@ctri.wisc.edu
608-265-5472
Mark Zehner
Contact
mark.zehner@wisc.edu
608-262-7568
Megan Piper, PhD
principal investigator · University of Wisconsin, Madison

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nicotine Oral Pouch

Start the discussion